On the flip side, vaccines Prevnar and Abrysvo underperformed expectations. Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025 RSV vaccine Abrysvo specifically floundered ...

Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

That shot, Abrysvo, brought in $198 million in the quarter, missing expectations by more than $300 million. Pfizer’s RSV vaccine has struggled to compete with one from GSK in a market that now ...

Pfizer’s PFE non-COVID operational revenues improved in the first three quarters of 2024, driven by its key in-line products like Vyndaqel and Eliquis, new launches like Abrysvo and newly ...

However, sales of some key drugs like Prevnar, Xeljanz and Ibrance and new RSV vaccine, Abrysvo declined in the quarter. Pfizer's COVID revenues include direct sales and alliance revenues from its ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an mRNA respiratory syncytial virus (RSV) ...

Abrysvo's season-to-date cumulative maternal ... But before we turn to the questions, I would like to close the year with one comment. Pfizer knows how to execute well when we set our focus ...

Prevnar family pneumococcal vaccine sales dipped 4% to $1.56 billion, and Abrysvo RSV vaccine sales slumped 62% to $198 million. Guidance: Pfizer reaffirms 2025 revenues of $61 billion-$64 billion ...